Abstract
Background: Cannabis legalization for medical and recreational purposes has been suggested as an effective strategy to reduce opioid and benzodiazepine use and deaths. We examined the county-level association between medical and recreational cannabis laws and poisoning deaths involving opioids and benzodiazepines in the US in 2002-2020.
Methods: Our ecologic county-level, spatiotemporal study comprised 49 states. Exposures were state-level implementation of medical and recreational cannabis laws and state-level initiation of cannabis dispensary sales. Our main outcomes were poisoning deaths involving any opioid, any benzodiazepine, and opioids with benzodiazepines. Secondary analyses included overdoses involving natural and semi-synthetic opioids, synthetic opioids, and heroin.
Results: Implementation of medical cannabis laws was associated with increased deaths involving opioids (rate ratio [RR]=1.14; 95% credible interval [CrI]: 1.11, 1.18), benzodiazepines (RR=1.19; 95%CrI: 1.12, 1.26), and opioids+benzodiazepines (RR=1.22; 95%CrI: 1.15, 1.30). Medical cannabis legalizations allowing dispensaries was associated with fewer deaths involving opioids (RR=0.88; 95%CrI: 0.85, 0.91) but not benzodiazepine deaths; results for recreational cannabis implementation and opioid deaths were similar (RR=0.81, 95%CrI: 0.75, 0.88). Recreational cannabis laws allowing dispensary sales was associated with consistent reductions in opioid- (RR=0.83; 95%CrI: 0.76, 0.91), benzodiazepine- (RR=0.79; 95%CrI: 0.68, 0.92), and opioid+benzodiazepine-related poisonings (RR=0.83; 95%CrI: 0.70, 0.98).
Conclusions: Implementation of medical cannabis laws was associated with higher rates of opioid- and benzodiazepine-related deaths, while laws permitting broader cannabis access, including implementation of recreational cannabis laws and medical and recreational dispensaries, were associated with lower rates. Estimated effects of expanded availability of cannabis seem dependent on the type of law implemented and its provisions.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interests: none declared
Similar articles
-
Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.JAMA Netw Open. 2020 Jan 3;3(1):e1919066. doi: 10.1001/jamanetworkopen.2019.19066.PMID: 31922561 Free PMC article.
-
Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study.BMJ. 2021 Jan 27;372:m4957. doi: 10.1136/bmj.m4957.PMID: 33504472 Free PMC article.
-
State Medical Cannabis Laws Associated With Reduction in Opioid Prescriptions by Orthopaedic Surgeons in Medicare Part D Cohort.J Am Acad Orthop Surg. 2021 Feb 15;29(4):e188-e197. doi: 10.5435/JAAOS-D-19-00767.PMID: 32404683
-
State marijuana laws and opioid overdose mortality.Inj Epidemiol. 2019 Sep 2;6:38. doi: 10.1186/s40621-019-0213-z. eCollection 2019.PMID: 31497489 Free PMC article. Review.
-
Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations.Am J Drug Alcohol Abuse. 2019;45(6):644-663. doi: 10.1080/00952990.2019.1669626. Epub 2019 Oct 11.PMID: 31603710 Free PMC article. Review.